Chief Executive Officer
Animab
Animab develops proprietary biotechnology solutions using oral antibodies to improve livestock gut health and performance. Their technology targets intestinal pathogens, reducing the need for antimicrobials in post-weaning piglets. This approach integrates research and animal science to enhance feed conversion and physiological development in livestock.
- Agriculture Technology
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$13.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Post-weaning piglets face a high risk of intestinal infections due to underdeveloped immune systems and changes in diet, leading to reduced growth rates and increased reliance on antimicrobials. Current methods for preventing these infections often involve broad-spectrum antibiotics, which contribute to antimicrobial resistance and disrupt the gut microbiome.
Solution
Animab develops orally administered antibodies that selectively target intestinal pathogens in livestock, specifically designed to improve gut health and reduce infections in piglets during the post-weaning phase. These antibodies are produced through a scalable microbial production process and integrated directly into animal feed. By neutralizing specific pathogens, Animab's technology minimizes the need for antimicrobials, leading to improved animal performance, better feed conversion rates, and a more balanced gut microbiome. The approach supports sustainable livestock farming by reducing reliance on antibiotics and promoting natural immunity.
Target Audience
Animab's primary customers are livestock farmers, particularly those raising piglets, seeking to reduce antimicrobial usage and improve animal health and performance in a sustainable manner.
Features
- Oral antibody technology targeting specific intestinal pathogens
- Scalable microbial production process for cost-effective antibody manufacturing
- Direct integration with animal feed for easy administration
- Reduced need for antimicrobials, minimizing antimicrobial resistance
- Improved gut health and microbiome balance in piglets
- Enhanced animal performance and feed conversion rates